Why Aethlon Medical Stock Skyrocketing?

  • Aethlon Medical Inc AEMD stock surged probably in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.'
  • The company recently announced the positive results from using its Hemopurifier in treating two critically ill COVID-19 patients, which is available under the FDA emergency use authorization (EUA).
  • The first patient was administered the Hemopurifier treatment daily, with adequate tolerance of the procedure and no signs of an allergic reaction, thrombotic complications, or hemolysis.
  • After the treatment, no demonstrable COVID-19 viremia, the active circulation of the virus in the bloodstream, was observed in the patient.
  • The treatment improved COVID-19 associated coagulopathy (CAC), lung injury, inflammation, and tissue injury.
  • Consequently, the company believes that the treatment can potentially remove exosomes with noxious microRNA cargo, resulting in patient recovery.
  • The second patient with coronary artery disease and diabetes, among other disorders, also had acute kidney injury, demonstrated in vivo removal of SARS-CoV-2 virus from the bloodstream of an infected patient.
  • The patient completed a six-hour Hemopurifier treatment without complications.
  • Price Action: AEMD shares are up 470.1% at $12.60 during the premarket session on the last check Wednesday.
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCovid-19